Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification

PHASE3CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

August 7, 2019

Study Completion Date

October 22, 2019

Conditions
Cataract
Interventions
DRUG

Difluprednate 0.05%

Dosage: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.

DRUG

Prednefrin

"1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.~\- Route of administration: topical ophthalmic"

Trial Locations (5)

44160

Catarata y Glaucoma de Occidente, Guadalajara

44620

Novam y Vita, Guadalajara

64710

Vision Cirugia Ambulatoria, Monterrey

06030

Hospital de la luz, Mexico City

06800

Fundación de asistencia privada Conde de Valenciana, Mexico City

All Listed Sponsors
lead

Laboratorios Sophia S.A de C.V.

INDUSTRY

NCT03693989 - Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification | Biotech Hunter | Biotech Hunter